NCT06022822 2026-03-18
Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
National Cancer Institute (NCI)
Ontario Clinical Oncology Group (OCOG)
Abramson Cancer Center at Penn Medicine
Hackensack Meridian Health
University of Washington
British Columbia Cancer Agency
Northwestern University
University of Alabama at Birmingham
City of Hope Medical Center
Ohio State University Comprehensive Cancer Center